Pimstone Simon N.'s Form 4/A amendment
AmendedXenon Pharmaceuticals Inc.XENE · filed Mar 8, 2022
- Accession no.
- 0001209191-22-017418
- Filed
- Mar 8, 2022
- Trade date
- Mar 8, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Mar 8, 2022
This filing lists 1 non-derivative transaction. It carries over 20 transactions from the original filing that it did not restate. Open-market sales total $1.68M. It was filed on the trade date.
This amendment restates part of 0001209191-22-017341 (filed Mar 8, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pimstone Simon N.CIK 0001620084 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.80F1 | −$77,000 | 193,135 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001209191-22-017341 (filed Mar 8, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2022 | Common Shares | MOption exerciseAcquired | +10,288 | $3.67F1 | +$37,756.96 | 220,474 | Direct | |
| Mar 4, 2022 | Common Shares | FTax withholdingDisposed | −963 | $31.42F2 | −$30,257.46 | 219,511 | Direct | |
| Mar 4, 2022 | Common Shares | SSaleDisposed | −4,532 | $30.66F3 | −$138,951.12 | 214,979 | Direct | |
| Mar 4, 2022 | Common Shares | SSaleDisposed | −4,793 | $30.56F4 | −$146,474.08 | 210,186 | Direct | |
| Mar 7, 2022 | Common Shares | MOption exerciseAcquired | +20,576 | $3.67F1 | +$75,513.92 | 230,762 | Direct | |
| Mar 7, 2022 | Common Shares | FTax withholdingDisposed | −1,990 | $30.23F5 | −$60,157.7 | 228,772 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −5,037 | $30.60F6 | −$154,132.2 | 223,735 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −4,517 | $30.49F7 | −$137,723.33 | 219,218 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −4,516 | $30.45F8 | −$137,512.2 | 214,702 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −4,516 | $30.44F9 | −$137,467.04 | 210,186 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.52 | −$76,300 | 207,686 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −7,500 | $30.50 | −$228,750 | 200,186 | Direct | |
| Mar 7, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.55 | −$76,375 | 197,686 | Direct | |
| Mar 8, 2022 | Common Shares | SSaleDisposed | −2,051 | $30.60 | −$62,760.6 | 195,635 | Direct | |
| Mar 8, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.10 | −$75,250 | 190,635 | Direct | |
| Mar 8, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.20 | −$75,500 | 188,135 | Direct | |
| Mar 8, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.55F11 | −$76,375 | 185,635 | Direct | |
| Mar 8, 2022 | Common Shares | SSaleDisposed | −2,500 | $30.50 | −$76,250 | 183,135 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2022 | Common Shares | MOption exerciseDisposed | −10,288 | $0.00 | $0 | 0 | Direct | |
| Mar 7, 2022 | Common Shares | MOption exerciseDisposed | −20,576 | $0.00 | $0 | 0 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
Referenced by the price of 2 transactions in Table I.
- F2
Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
Referenced by the price of 1 transaction in Table I.
- F3
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.49 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F4
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.53 to $30.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the closing price of the Company's common shares on March 4, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
Referenced by the price of 1 transaction in Table I.
- F6
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4865 to $30.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F7
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.480 to $30.645, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F8
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.4100 to $30.4750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F9
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.40 to $30.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F11
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.55 to $30.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.800 to $30.880, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
Remarks
This amendment corrects the share price that was inaccurately reported on the original Form 4 due to a clerical error.